Trial Profile
Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 20 Dec 2021 Status changed from active, no longer recruiting to completed.
- 11 Oct 2019 Results (n=845) published in the American Journal of Respiratory and Critical Care Medicine.
- 18 May 2018 Planned End Date changed from 15 Jan 2020 to 30 Jun 2018.